Drug-coated balloon-only strategy for percutaneous coronary intervention of de novo left main coronary artery disease: the importance of proper lesion preparation / 医学前沿

This retrospective single-center registry study included all consecutive patients who underwent percutaneous coronary intervention (PCI) for a de novo left main coronary artery lesion using drug coated-balloon (DCB)-only strategy between August 2011 and December 2018. To best of our knowledge, no previous studies of DCB-only strategy of treating de novo left main coronary artery disease, exist. The primary endpoint was major adverse cardiovascular events (MACEs) including cardiac death, non-fatal myocardial infarction, and target lesion revascularization (TLR). The cohort was divided into two groups depending on weather the lesion preparation was done according to the international consensus group guidelines. Sixty-six patients (mean age 75±8.6, 72% male), 52% of whom had acute coronary syndrome, underwent left main PCI with the DCB-only strategy. No procedural mortality and no acute closures of the treated left main occurred. At 12 months, MACE and TLR occurred in 24% and 6% of the whole cohort, respectively. If the lesion preparation was done according to the guidelines, the MACE and TLR rates were 21.2% and 1.9%. Left main PCI with the DCB only-strategy is safe leading to acceptable MACE and low TLR rates at one year, if the lesion preparation is done according to the guidelines.

Antiagregación plaquetaria: stents, isquemia y sangrado ¿Qué sabemos al respecto? / Platelet antiaggregation: stents, ischemia and bleeding What do we know about it?

Antiplatelet therapy and percutaneous coronary intervention are two of the most important interventions in the management of coronary artery disease. In the last 20 years there has been groundbreaking advances in the pharmacotherapy and stent technology. Bleeding is the most feared complication of antiplatelet therapy, mainly due to the increase in major adverse cardiovascular events besides the bleeding itself. Different clinical decision tools have developed with the aim to define which patients have a high ischemic or bleeding risk, thus individualizing treatment.

Riesgo de resangrado en hemorragia digestiva alta según la escala de Glasgow-Blatchford: herramienta de triaje / Upper gastrointestinal hemorrhage re-bleeding risk according to the Glasgow-Blatchford scale: a triage tool

Resumen Introducción: Con la escala de Glasgow-Blatchford (EG-B) se califica mediante datos clínicos, el riesgo de resangrado después de hemorragia del tubo digestivo alto (HTDA); y con las escalas de Forrest y Dagradi, mediante endoscopia. Objetivo: Evaluar la capacidad de la EG-B para identificar riesgo de resangrado a 30 días después de una HTDA; el estándar de oro de comparación fue la endoscopia. Método: Se analizaron 129 expedientes de pacientes con HTDA y endoscopia. Se cuantificaron las escalas de Glasgow-Blatchford, Forrest y Dagradi; se calculó sensibilidad, especificidad y área bajo la curva ROC (ABC-ROC) del riesgo de resangrado reportado por EG-B. Resultados: La EG-B identificó a 53 pacientes con riesgo bajo de resangrado (41.09 %) y 76 con riesgo alto (58.91 %). Con la endoscopia se identificó a 107 pacientes con hemorragia no variceal (82.94 %), 98 con riesgo bajo (89.9 %) y 11 con riesgo alto (10.09 %); además, 22 pacientes con hemorragia variceal (17.05 %), 12 con riesgo bajo (54.54 %) y 10 con riesgo alto (45.45 %). La EG-B mostró sensibilidad de 0.857, especificidad de 0.462 y ABC-ROC de 0.660. Conclusiones: La EG-B es sencilla, objetiva y útil para identificar riesgo de resangrado después de HTDA; se sugiere como herramienta de triaje en urgencias.

Abstract Introduction: The Glasgow-Blatchford scale (GBS) classifies the risk of re-bleeding after upper gastrointestinal bleeding (UGIB) using clinical data, whereas the Forrest and Dagradi scales do it by endoscopy. Objective: To assess GBS’s ability to identify re-bleeding risk within 30 days of an UGIB, using endoscopy as the gold standard for comparison. Method: 129 medical records of patients with UGIB and endoscopy were analyzed. The Glasgow-Blatchford, Forrest and Dagradi scales were quantified; sensitivity, specificity and area under the ROC curve (AUC-ROC) of GBS-reported re-bleeding risk were calculated. Results: GBS identified 53 patients with low re-bleeding risk (41.09 %) and 76 with high risk (58.91 %). Endoscopy identified 107 patients with non-variceal bleeding (82.94 %): 98 with low risk (89.9 %) and 11 with high risk (10.09 %); in addition, it identified 22 patients with variceal hemorrhage (17.05 %): 12 with low risk (54.54 %) and 10 with high risk (45.45 %). GBS showed a sensitivity of 0.857, specificity of 0.462 and an AUC-ROC of 0.660. Conclusions: GBS is simple, objective and useful to identify the risk of re-bleeding after UGIB; it is suggested as a triage tool in the emergency department.

Knowledge gaps about Oral Anticoagulant in Saudi Patients

Patients with atrial fibrillation (AF) are at a higher risk of thrombotic stroke. Therefore treatment with an oralanticoagulant (OAC) has been proven to prevent stroke, however, the bleeding side effect of OAC is the concernfor both physicians and patients. Patients’ knowledge of the stroke and bleeding related to AF is lacking inSaudi Arabia. We conducted this study to assess the knowledge of patients on AF related to stroke and bleedingfrom OAC. Method: this is a cross-sectional study conducted in a tertiary care university center in Riyadh SaudiArabia. A validated questioner provided to patients or patients’ relatives who were diagnosed as permanent AFon OAC, 15 years of age or older who consented to participate in answering the questionnaire. Results: Of 229patients analyzed 46% were male and 54% were female; 58.8% in the age of 56-75 years. They were obese andhad a sedentary lifestyle. 42% knew AF symptoms, 28.9% knew AF can cause stroke, 39% knew bleeding sideeffect of OAC and there were no gender differences. Conclusion: This study revealed poor knowledge about AF,stroke, and bleeding side effects, and this mandate urgent strategy for patients’ education in Saudi Arabia.

Anticoagulación en enfermedad tromboembólica venosa / Anticoagulant therapy in venous thromboembolic disease

INTRODUCCIÓN: La enfermedad tromboembólica venosa está comprendida por la trombosis venosa profunda y el tromboembolismo pulmonar, las cuales son enfermedades comunes con alta morbilidad y mortalidad, incluso antes del diagnóstico. El tratamiento está basado principalmente en la terapia anticoagulante, con diferentes opciones dependiendo del ámbito clínico y la estabilidad del paciente (terapia oral vs parenteral). Objetivo: Revisar las diferentes opciones y escenarios clínicos para la indicación de terapia anticoagulante, basados en la evidencia médica actual. Metodología: Se realizó una búsqueda sistemática en las bases de datos PubMed, Scopus, Google Académico y Scielo sobre estudios que evaluaran la indicación de la terapia anticoagulante en pacientes con diagnóstico de enfermedad tromboembólica venosa, principalmente, estudios aleatorizados controlados y metaanálisis. Discusión y Resultados: Fueron encontrados estudios aleatorizados controlados donde se evidencian menores tasas de sangrado y recurrencia de la enfermedad tromboembólica venosa a favor de los anticoagulantes directos, excluyendo algunas situaciones especiales como cáncer y enfermedad renal crónica avanzada. Conclusión: La terapia anticoagulante es el pilar del tratamiento en la enfermedad tromboembólica, disminuyendo la morbilidad y mortalidad de esta entidad, aunque aumenta el riesgo de sangrado. Anteriormente, los anticoagulantes antagonistas de la vitamina K eran la única opción terapéutica, pero con altas tasas de sangrado, afortunadamente desde hace algunos años contamos con los anticoagulantes directos con mejores perfiles de seguridad y menor tasa de sangrado.

ABSTRACTS: Venous thromboembolic disease includes deep venous thrombosis and pulmonary embolism, which are common diseases with high morbidity and mortality. The treatment is based mainly on anticoagulant therapy, with different options depending on clinic context and patient stability (oral vs parenteral therapy). Objective: To review evidence based medical information regarding the use of anticoagulant therapy in venous thromboembolism. Methods: We performed a systematic review of PubMed, Scopus, Google scholar and Scielo databases, of randomized controlled studies and meta-analysis evaluating anticoagulant therapy in patients with thromboembolic venous disease. Results: Except for tromboembolic disease in patients with cancer or chronic kidney disease anticoagulation with direct (new) oral agents led to less bleeding episodes and lower relapse rate. Conclusion: anticoagulant therapy is the basis of treatment for thromboembolic disease, decreasing morbidity and mortality. New oral anticoagulants' are associated to better clinical results, notwithstanding a slight increase in bleeding episodes.

Conducta antitrombótica en pacientes con fibrilación auricular e ictus isquémico. Hospital Faustino Pérez. Año 2017 / Antithrombotic behavior in patients with auricular fibrillation and ischemic stroke. Hospital ¨Faustino Pérez¨. 2017

Introducción: se realizó un estudio observacional transversal en pacientes con fibrilación auricular ingresados con ictus isquémico en la sala de neurología del Hospital Faustino Pérez el año 2017. Objetivo: describir la conducta antitrombótica en estos pacientes previa al ingreso en relación con: riesgo de embolismo y sangrado, factores de riesgo de sangrado, tratamiento antitrombótico indicado. Materiales y métodos: el universo del estudio fue de 40 pacientes con fibrilación auricular e ictus isquémico. Durante el ingreso a los pacientes y/o familiares se les aplicó una encuesta para la obtención de la información. Se determinó el riesgo de embolismo y sangrado según las escalas CHA2DS2-VASc y HAS-BLED respectivamente. Resultados: predominó el grupo de edades de 75-84 años con 50%, 95% de los pacientes presentó alto riesgo de embolismo, los factores de riesgo de sangrado más frecuente fueron la edad > 65 años y la hipertensión arterial con 95% y 85% respectivamente, 70 % presentó bajo riesgo de sangrado y en pacientes con alto riesgo de sangrado el 20% presentó puntuación de 3 puntos, 60% de los pacientes no presentó tratamiento antitrombótico antes del ingreso con ictus isquémico asociado a fibrilación auricular, 35 % fue tratado con antiagregantes plaquetario y solo 5% con tratamiento anticoagulante. Conclusiones: la mayoría de los pacientes fueron mayores de 75 años con alto riesgo de embolismo y bajo riesgo de sangrado por lo cual era recomendada la anticoagulación. Los anticoagulantes orales son poco indicados en pacientes con fibrilación auricular a pesar de asociarse a mayor supervivencia (AU).

Introduction: it was carried out a transversal observational study in the hospitalized patients with atrial fibrillation and ischemic stroke in the neurology service of Faustino Pérez Hospital in 2017. Objective: To delineate the antithrombotic management in these patients prior to be admitted in the hospital in regard to embolism risk and bleeding risk, bleeding risk factors, antithrombotic therapy indicated. Materials and methods: The universe of the study was 40 patients with AF and ischemic stroke. During the hospitalization of the patients were applied a survey to patients and/or their relatives for getting the information. The embolism risk and bleeding risk were defined according to CHA2DS2-VASc and HAS-BLED scales respectively. Results: The most prevalence ages group was of the 75-84 year-old, in 95% of the patients the embolism risk was high, the most frequent bleeding risk factors for bleeding were age over 65 years and arterial hypertension with 95% y 85% respectively, in 70% bleeding risk was low and in patients with high bleeding risk the 20% carried a score of 3 points, 60% of the patients hadn't antithrombotic therapy prior to be hospitalized with ischemic stroke, 35 % used antiplatelet Agents and only 5% used anticoagulants therapy. Conclusion: The most hospitalized patients with ischemic stroke and AF had high embolism risk and low bleeding risk and should be treated with oral anticoagulant therapy. Oral anticoagulants are underused patients with atrial fibrillation despite of being associated with more survival (AU).

Nuevos anticoagulantes orales y antiagregantes plaquetarios, en el período perioperatorio de cirugía no cardíaca. Parte 1: Nuevos anticoagulantes directos / Novel oral anticoagulants and new platelet antiaggregants, in the perioperative period of non cardiac surgery. Part 1: New direct oral anticoagulants

Due to the high frequency of patients with atrial fibrillation, thromboembolic disease, users of mechanical prosthetic valves, among other pathologies, in addition to their established use and advantages over vitamin K inhibitors, the use of novel oral anticoagulants (NOAC) is becoming more frequent in the perioperative period. The anesthesiologist must consider the thromboembolic risk of the patient, risk of bleeding, the half-life of the NOAC in used, in addition to the patients renal and hepatic function. Rivaroxaban and Apixaban should be suspended according to the risk of surgical bleeding, 24 to 36 hours before a surgery with a low risk of bleeding and 48 hours for high. In the case of Dabigatran, these times should be extended. These drugs are safe in the perioperative period and in most cases, it is not necessary to do a bridging therapy with heparin. The reversal of this type of drugs is also of special interest, currently available with specific methods for dabigatrán. Antidotes for other drugs are being studied. The decision of using a neuraxial block should be evaluated according to the time in which the patient discontinued the drugs and their renal function, specially in the case of Dabigatran.

Por la alta frecuencia de pacientes con fibrilación auricular, enfermedad tromboembólica, usuarios de válvulas protésicas mecánicas, entre otras patologías, además, de su establecido uso y ventajas con respecto a los inhibidores de vitamina K, cada vez es más frecuente el uso de los nuevos anticoagulantes orales (NACO) en el perioperatorio. Su manejo tiene características especiales. Debemos considerar el riesgo tromboembólico del paciente, de sangrado, la vida media del NACO utilizado, además de las funciones depurativas del organismo. Rivaroxaban y apixaban deben ser suspendidos según el riesgo de sangrado quirúrgico, 24 a 36 horas previo a una cirugía de bajo riesgo de sangrado y 48 horas para una de alto riesgo. En el caso del Dabigatrán y por la importancia de la función renal en su eliminación, estos tiempos deben extenderse. Estos fármacos son seguros en el perioperatorio y en la mayor parte de los casos no es necesario hacer terapia puente con heparina. La reversión es también de especial interés. Actualmente, se dispone con métodos específicos para dabigatrán y potenciales antídotos para los otros fármacos. La posibilidad de realizar un bloqueo neuroaxial debe ser evaluado según el tiempo en que el paciente suspendió los medicamentos y su función renal en caso de Dabigatrán.

Nuevos anticoagulantes orales y antiagregantes plaquetarios, en el período perioperatorio de cirugía no cardíaca. Parte 2: Nuevos antiagregantes plaquetarios / Novel oral anticoagulants and new platelet antiaggregants, in the perioperative period of non cardiac surgery. Part 2: New platelet antiaggregants

Coronary disease and the cerebro-vascular accidents represent the first causes of mortality worldwide. Platelet antiaggregants are fundamental for the management and prevention of these diseases. Aspirin is still the most used drug in this group, but new antagonists of the ADP receptor and glycoprotein IIb/IIIa antagonists have been added with increasing frequency, so its management in the perioperative period deserves special attention. There are clinical guidelines that help us decide on the maintenance or suspension of these drugs in the perioperative period, all of which are based mainly on expert recommendations and state that the decision should be taken jointly by the entire treatment team. If their antiplatelet effects are not desired, Clopidogrel and Ticagrelor should be discontinued at least 5 days before surgery, and at least 7 days with Prasugrel. Cangrelor should be discontinued at least 60 minutes prior to the procedure. After the suspension of glycoprotein IIb/IIIa inhibitors, platelet activity returns to normal at 8 hours with Tirofiban and Eptifibatide, and up to 24 to 48 hours with Abciximab. There are also recommendations regarding the use of neuroaxial anesthesia in patients who use this type of drug.

La enfermedad coronaria y el accidente cerobrovascular representan las primeras causas de mortalidad a nivel mundial. Los antiagregantes plaquetarios, son fundamentales para el manejo y prevención de estas enfermedades. La Aspirina sigue siendo el fármaco más utilizado de este grupo, pero se han ido agregando nuevos antagonistas del receptor de ADP y antagonistas de la Glicoproteína IIb/IIIa con cada vez mayor frecuencia, por lo que su manejo en el perioperatorio merece atención especial. Existen guías clínicas que nos ayudan a decidir la mantención o suspensión de estos fármacos en el perioperatorio, todas ellas son basadas principalmente en recomendaciones de expertos y recomiendan que la decisión sea tomada en conjunto por todo el equipo tratante. Si se quiere suspender estos fármacos y evitar sus efectos antiplaquetarios, clopidogrel y ticagrelor se deben suspender al menos 5 días previo a la cirugía, y al menos 7 días en el caso de prasugrel. Cangrelor se debe suspender al menos 60 minutos previo al procedimiento. Luego de la suspensión de los inhibidores de glicoproteína IIb/IIIa, la actividad plaquetaria vuelve a la normalidad a las 8 horas en el caso de tirofiban y eptifibatide, y hasta 24 a 48 horas en el caso de abciximab. Existen también recomendaciones con respecto al uso de anestesia neuroaxial en los pacientes usuarios de este tipo de fármacos.

Analysis of the Alternate Application of Anticoagulant Drugs and Coagulant Drugs in the Patients with Thrombosis and Hemorrhage / 中国药师

A 72-year-old female patient was admitted to our hospital due to chronic cough, expectoration and dyspnea for 10 years,aggravated with intermittent fever for 1 month. She was diagnosed as acute exacerbation of chronic bronchitis,chronic pulmonary heart disease,cardiac function class IV,bilateral lower extremity venous thrombosis and thrombocytopenia. The application of antico-agulant drugs and coagulant drugs in the patient needed to be well weighed with the methods of the bleeding score system combined with clinical assessment of actual risk of bleeding. The interactions of drugs harmful to the patient should be considered and the prognosis of the patient should also be evaluated with careful clinical thought to reduce the patient's risk.

Anticoagulation Effect and Bleeding Risk of Combination Therapy with SAFI and Aspirin / 中国药学杂志

OBJECTIVE: To explore the curative effect of combination therapy with salvianolate injection (SAFI) and aspirin on anti-platelet aggregation and blood coagulation function, provide the experimental evidence for clinical consequence use of combination therapy with traditional Chinese medicine and western medicine. METHODS: The bleeding time was measured by cutting tail evaluating of combination of drugs; platelet maximum aggregation rate induced by ADP, AA, collagen and thrombin in rats was determined by absorbance method using a microplate reader; blood coagulation of the four indicators were measured by the semiautomatic blood agglutination instrument. RESULTS: SAFI had nearly no effects on aspirin group's bleeding time. The effect on blood platelets aggregation compared with control group, SAFI group and aspirin group could significantly reduce platelet aggregation induced by ADP, AA, collagen and thrombin in normal rats(P<0.01). Combinative group could significantly increase aspirin group's anti-platelet aggregation induced by ADP, AA, collagen and thrombin in normal rats(P<0.01, P<0.05). Coagulation function SAFI can reduced aspirin group's TT after the combination therapy. CONCLUSION: SAFI can increase anticoagulation effect of aspirin, and have no effect on aspirin's bleeding risk.

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention / 中华医学杂志(英文版)

Background@#There was still conflict on the antithrombotic advantage of ticagrelor versus clopidogrel among East Asian population with acute coronary syndrome (ACS). We considered that the baseline bleeding risk might be an undetected key factor that significantly affected the efficacy of ticagrelor.@*Methods@#A total of 20,816 serial patients who underwent percutaneous coronary intervention (PCI) from October 2011 to August 2014 in the General Hospital of Shenyang Military Region were enrolled in the present study. Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk. The primary outcome was net adverse clinical events (NACEs) defined as major adverse cardiac or cerebral events (MACCE, including all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, or stroke) and any bleeding during 1-year follow-up. Comparison between ticagrelor and clopidogrel was adjusted by propensity score matching (PSM).@*Results@#Among the 20,816 eligible PCI patients who were included in this study, there were 1578 and 779 patients in the clopidogrel and ticagrelor groups, respectively, after PSM, their clinical parameters were well matched. Patients receiving ticagrelor showed comparable NACE risk compared with those treated by clopidogrel (5.3% vs. 5.1%, P = 0.842). Furthermore, ticagrelor might reduce the MACCE risk in patients with low bleeding risk but increase MACCE in patients with moderate-to-high bleeding potential (ticagrelor vs. clopidogrel, low bleeding risk: 2.5% vs. 4.9%, P = 0.022; moderate-to-high bleeding risk: 4.8% vs. 3.0%, P = 0.225; interaction P = 0.021), with vast differences in all bleeding (low bleeding risk: 1.5% vs. 0.8%, P = 0.210; moderate-to-high bleeding risk: 4.8% vs. 3.0%, P = 0.002; interaction P = 0.296).@*Conclusion@#Among real-world Chinese patients with ACS treated by PCI, ticagrelor only showed superior efficacy in patients with low bleeding risk but lost its advantage in patients with moderate-to-high bleeding potential.

The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is essential after percutaneous coronary intervention (PCI), while many studies have focused on determining the optimal degree of platelet inhibition and optimal DAPT duration to minimize complications after PCI. Current guidelines developed by the American College of Cardiology/American Heart Association and the European Society of Cardiology summarize previous studies and provide recommendations. However, these guidelines are mainly based on Western patients, and their characteristics might differ from those of East Asian patients. Previous data suggested that East Asian patients have unique features with regard to the response to antiplatelet agents. On comparing Western and East Asian patients, it was found that East Asian patients have a lower rate of ischemic events and higher rate of bleeding events after PCI, despite a higher on-treatment platelet reactivity, which is referred to as the “East Asian paradox.” As the main purpose of DAPT is to minimize ischemic and bleeding complications after PCI, these differences should be clarified before adopting the guidelines for East Asian patients. Therefore, in this article, we will review various issues regarding DAPT in East Asian patients, with a focus on the unique characteristics of East Asian patients, previous studies regarding antiplatelet agents in East Asian patients, and a guideline from an East Asian perspective.

Effects of different anti thrombotic strategies on bleeding risk, cardiac events and quality of life in elderly patients with acute non ST segment elevation myocardial infarction complicated with atrial fibrillation / 中国生化药物杂志

Objective To investigate the effects of different anti thrombotic strategies on the risk of bleeding, cardiac events and quality of life in elderly patients with acute non ST segment elevation myocardial infarction.MethodsElderly patients with acute non ST elevation myocardial infarction 200 cases of complication in patients with atrial fibrillation, are in our hospital from May 2013 to December 2015 were cardiovascular department, after discharge according to different antithrombotic strategy, according to the 5 groups, including 40 cases of A group, 75mg/d+ 100mg/d treatment with clopidogrel and aspirin;B group 40 cases.Using warfarin therapy;40 cases in group C, 75mg/d or 100mg/d+ with clopidogrel aspirin warfarin therapy;40 cases in group D, using 75mg/d+ 100mg/d+clopidogrel aspirin warfarin therapy, group E received 75mg/d+ clopidogrel aspirin 100mg/d plus warfarin therapy, based on the use of psychological intervention.The risk of bleeding, cardiac events and quality of life scores were compared.ResultsStatistical analysis showed that the incidence of major cardiac events in E group (2.5%) and the quality of life were optimal (the data are statistically significant compared to P<0.05, A, B);C, D, E groups, the risk of major bleeding rate compared with no significant difference.ConclusionThe application of drugs and psychological intervention in the treatment of elderly patients with acute non ST segment elevation myocardial infarction patients can be more effective.

A pilot study of regional citrate anticoagulation for continuous renal replacement therapy in patients with acute kidney injury at high risk of bleeding / 中华急诊医学杂志

Objective To explore the advantages and disadvantages of regional citrate anticoagulation (RCA) mode by comparing to non-anticoagulation mode for continuous renal replacement therapy (CRRT)in patients with acute kidney injury (AKI) at high risk of bleeding.Methods The criterion for inclusion of patients was stage 3 of AKI selected according to Kidney Disease Improving Global Outcomes guideline.And those patients had high risk factors of bleeding as well as such as post-major opertion,coagulopathy (prothrombin time or activated partial thromboplastin time ＞ 1.5 times the normal control,or prothrombin time ＞ 18 s,activated partial thromboplastin time ＞ 60 s),thrombocytopenia (＜ 50 × 109/L),and combined therapy with anticoagulant,antiplatelet or thrombolytic drugs.The CRRT was initiated within 4 h after randomization.The exclusion criteria was severe liver failure (serum total bilirubin ＞ 171 μmmol/L).Continuous venovenous hemodiafiltration mode was employed in both groups,and the filter was changed routinely every 72 h,unless clotting developed in the extracorporeal circuit.Because the commercial calcium-free dialysate was not available in the market,this dialysate was prepared by the intensive care unit (ICU) nurses.Results Thirty two patients were equally divided in those two groups,and most of them were admitted to ICU after major surgery.There were no significant differences between the groups in data of blood gas analysis,hepatic/renal/coagulative functions,electrolyte,hemoglobin and platelet count before or after CRRT.The filter was more durable in RCA mode than that in non-RCA mode determined through Kaplan-Meier curve analysis (x2 =9.707,P =0.002),with the mean time (h) 36.01 (26.61-45.42)vs.22.04 (18.35-25.73).More packed red blood cells and platelet were required in non-RCA mode than those in RCA mode during CRRT.There was no significant difference in ICU mortality between RCA mode and non-RCA mode with 7/16 vs.9/16,P =0.724.Severe blood loss and malignant arrhythmia events did not occur in both modes.The body temperature,systemic electrolyte,post-filter ionized calcium levels and the ratio of total to ionized systemic calcium were basically preserved at a target range in RCA group during CRRT.Conclusions RCA-CRRT is a safe and effective mode for AKI patient with high risk of bleeding,which can extend the durability of filter,and lower the risk of blood loss.However,the study failed to show a mortality benefit with the RCA mode,and it could also increase the workload of nurses under the current domestic setting.

A pilot study of regional citrate anticoagulation for continuous renal replacement therapy in patients with acute kidney injury at high risk of bleeding / 中华急诊医学杂志

Objective To explore the advantages and disadvantages of regional citrate anticoagulation (RCA) mode by comparing to non-anticoagulation mode for continuous renal replacement therapy (CRRT)in patients with acute kidney injury (AKI) at high risk of bleeding.Methods The criterion for inclusion of patients was stage 3 of AKI selected according to Kidney Disease Improving Global Outcomes guideline.And those patients had high risk factors of bleeding as well as such as post-major opertion,coagulopathy (prothrombin time or activated partial thromboplastin time ＞ 1.5 times the normal control,or prothrombin time ＞ 18 s,activated partial thromboplastin time ＞ 60 s),thrombocytopenia (＜ 50 × 109/L),and combined therapy with anticoagulant,antiplatelet or thrombolytic drugs.The CRRT was initiated within 4 h after randomization.The exclusion criteria was severe liver failure (serum total bilirubin ＞ 171 μmmol/L).Continuous venovenous hemodiafiltration mode was employed in both groups,and the filter was changed routinely every 72 h,unless clotting developed in the extracorporeal circuit.Because the commercial calcium-free dialysate was not available in the market,this dialysate was prepared by the intensive care unit (ICU) nurses.Results Thirty two patients were equally divided in those two groups,and most of them were admitted to ICU after major surgery.There were no significant differences between the groups in data of blood gas analysis,hepatic/renal/coagulative functions,electrolyte,hemoglobin and platelet count before or after CRRT.The filter was more durable in RCA mode than that in non-RCA mode determined through Kaplan-Meier curve analysis (x2 =9.707,P =0.002),with the mean time (h) 36.01 (26.61-45.42)vs.22.04 (18.35-25.73).More packed red blood cells and platelet were required in non-RCA mode than those in RCA mode during CRRT.There was no significant difference in ICU mortality between RCA mode and non-RCA mode with 7/16 vs.9/16,P =0.724.Severe blood loss and malignant arrhythmia events did not occur in both modes.The body temperature,systemic electrolyte,post-filter ionized calcium levels and the ratio of total to ionized systemic calcium were basically preserved at a target range in RCA group during CRRT.Conclusions RCA-CRRT is a safe and effective mode for AKI patient with high risk of bleeding,which can extend the durability of filter,and lower the risk of blood loss.However,the study failed to show a mortality benefit with the RCA mode,and it could also increase the workload of nurses under the current domestic setting.

Benefits of Thromboelastography and Thrombin Generation Assay for Bleeding Prediction in Patients With Thrombocytopenia or Hematologic Malignancies

BACKGROUND: Thromboelastography (TEG) provides comprehensive information on the whole blood clot formation phases, whereas thrombin generation assay (TGA) reveals the endogenous thrombin levels in plasma. We investigated the potential significance of TEG and TGA parameters for prediction of clinical bleeding in hematologic patients on the basis of the patient's platelet levels. METHODS: TEG and TGA were performed in 126 patients with thrombocytopenia or hematologic malignancies. The bleeding tendencies were stratified on the basis of the World Health Organization bleeding grade. RESULTS: Maximum amplitude (MA) and clot formation in TEG and endogenous thrombin potential (ETP) in TGA showed significant associations with high bleeding grades (P=0.001 and P=0.011, respectively). In patients with platelet counts ≤10×10⁹/L, low MA values were strongly associated with a high bleeding risk. For bleeding prediction, the area under the curve (AUC) of MA (0.857) and ETP (0.809) in patients with severe thrombocytopenia tended to be higher than that of platelets (0.740) in all patients. Patients with platelet counts ≤10×10⁹/L displayed the highest AUC of the combined MA and ETP (0.929). CONCLUSIONS: Both TEG and TGA were considered to be good predictors of clinical bleeding in patients with severe thrombocytopenia. Combination of the ETP and MA values resulted in a more sensitive bleeding risk prediction in those with severe thrombocytopenia.

Short term bleeding risk assessment of bivalirudin combined with ticagrelor in patients with STEMI during emergency PCI / 重庆医学

Objective To observe the bleeding risk of bivalirudin combined with ticagrelor in patients with acute ST segment elevation myocardial infarction (STEMI) during emergency percutaneous coronary intervention (PCI) .Methods A retrospective a‐nalysis of 458 patients with STEMI who underwent emergency PCI in our hospital was performed .All patients were divided into the bivalirudin group (217 cases) and the standard heparin group(241 cases) according to the anticoagulation scheme during PCI opera‐tion .All patients administered the dual antiplatelet therapy of aspirin 100 mg and ticagrelor 180 mg before surgery .Then ,all pa‐tients were administered dual antiplatelet therapy of aspirin 100 mg once daily and ticagrelor 90 mg twice daily for a long time .The clinical data were analyzed and the bleeding situation within 72 h after PCI was compared between the two groups .Results There were no statistically significant differences in gender ,age ,body mass ,smoking proportion ,occurrence rates of accompanying and complicating diseases ,RBC count ,platelet count ,Hb and PT before PCI between the two groups(P>0 .05) .The bleeding incidence rate in the bivalirudin group was significantly lower than that in the standard heparin group ,and the difference was statistically sig‐nificant (χ2 =8 .455 ,P<0 .05) .Conclusion Compared with standard heparin ,on the basis of ticagrelor use ,giving bivalirudin dur‐ing PCI process can reduce the bleeding risk of patients .

The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding / 中华危重病急救医学

ObjectiveTo evaluate whether AN69 ST membrane would prolong filter lifetime in continuous renal replacement therapy (CRRT) without anticoagulation in patients with high risk of bleeding.Methods A single-center, prospective, randomized, double-blind control trial with crossover design was conducted. From March 1st to December 31st in 2013, patients who were admitted to Department of Critical Care Medicine of the Fourth Hospital of Hebei Medical University meeting CRRT treatment indications, but could not receive systemic anticoagulation because of high risk of bleeding were studied. The selected patients were randomly divided into two groups according to a random number table, and four filters consisting of two AN69 ST100 membrane filters (A) and two traditional AN69 M100 membrane filters (B) were used for them. GroupⅠ with the filter order of A-B-A-B, and groupⅡ with the order of B-A-B-A. The clinical data of patients was recorded in detail, and conventional AN69 ST and AN69 membrane filter lifetime, their influence on coagulability, and the incidence of bleeding complications were compared.Results Seventeen patients were enrolled, with 10 in groupⅠ, and 7 in groupⅡ. The basic medical characteristics including gender, age, acute physiology and chronic health evaluationⅡ (APAECHⅡ) score, sequential organ failure score (SOFA), Acute Renal Injury Network (AKIN) stage, activated partial thromboplastin time (APTT), prothrombin time (PT), international normalized ratio (INR), platelet count (PLT), and use of mechanical ventilation were not significantly different between two groups. But the use of vasoactive drug was more frequent in groupⅡcompared with that of groupⅠ[100.0% (7/7) vs. 30.0% (3/10),χ2 = 8.330,P = 0.010]. AN69 ST filter lifetime (n =34) was (15.92±2.10) hours, there was no statistically significant difference compared with that of AN69 membrane (t = 0.088,P = 0.942), filter lifetime of which (n = 34) was (16.12±1.38) hours. It was also found by Kaplan-Meier survival analysis that there was no significant difference between the two membrane filter lifetime (χ2=1.589,P =0.208). Logistic regression analysis showed that the life of the first filter was not correlated with coagulation indicators, including APTT, PT, INR, and PLT [APTT: odds ratio (OR) = 0.977, 95% confidence interval (95%CI) = 0.892-1.071, P = 0.623; PT:OR = 1.001, 95%CI = 0.901-1.109,P = 0.988; INR:OR = 1.078, 95%CI = 0.348-3.340,P = 0.896;PLT:OR = 0.996, 95%CI = 0.974-1.019,P = 0.735]. The application rate of vasoactive drugs, which was different between two groups for basic medical indications showed no effect on filter life time (OR = 2.541, 95%CI = 0.239-26.955,P = 0.439). Reasons of clotting in filters were also analyzed, and it was found that blood coagulation in the filter ranked the top (88.2%), and the other reasons were catheter-related problems, death, and unscheduled transport. No difference in blood coagulation function was found in both groups after treatment for 12 hours, and there was no bleeding complication.ConclusionDuring the CRRT without systemic anticoagulant, both surface-treatment with polyethyleneimine AN69 and AN69 ST membrane cannot prolong filter lifetime.

The Use of Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy for Children with a High Risk of Bleeding

PURPOSE: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT. METHODS: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3). RESULTS: Forty patients (25 male and 15 female; mean age, 8.2+/-6.6 years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P=0.001). The mean hemofilter lifespan with NM was greater than with heparin (P=0.018). No patient experienced a major bleeding event during treatment with NM. CONCLUSION: NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.

A Multi-Center Phase III Clinical Trial to Assess the Influence to Bleeding and Anticoagulant Effect of Nafamostat Mesilate (Futhan) in Hemodialysis Patients with High Bleeding-Risk / 대한신장학회잡지

BACKGROUND: Routine hemodialysis is performed with systemic anticoagulation, usually with heparin, to prevent thrombosis in the extracorporeal blood circuit. However, systemic anticoagulation can produce hemorrhagic complications in patients at high risk of bleeding. To minimize the risk of bleeding, a number of alternative regimens has been proposed, however, each of those methods has its own limitations and complication. METHODS: 58 hemodialysis patients at risk for bleeding due to previous surgery or hemorrhagic complication were treated with Futhan as regional anticoagulant and compared with that of low-dose heparin anticoagulation. There were 29 (50%) postoperative cases and 29 (50%) cases of hemorrhage from various sites. RESULTS: The exacerbation of bleeding by hemodialysis was noted in only 4% in heparin treated group and none in Futhan group. Clotting times at site A (intracorporeal circulation) were not prolonged with Futhan, whereas those of heparin were prolonged slightly, which is not statistically significant. Degrees of residual blood in the dialyzer and blood clottings in the venous drip-chamber were less in Futhan than in heparin group. Adverse reactions related to Futhan therapy were minor and the incidence of adverse reactions was comparable in both groups. CONCLUSION: Futhan is a safe and effective regional anticoagulant for hemodialysis especially for patients with high bleeding risk.